Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novo Nordisk A/S ADR
(NY:
NVO
)
127.51
-7.37 (-5.46%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novo Nordisk A/S ADR
< Previous
1
2
3
4
5
6
7
8
9
...
60
61
Next >
Netflix, Eli Lilly Lead 5 Fast Growers Near Buy Points
Today 8:51 EDT
NFLX is among four stocks on the list that's actionable now.
Via
Investor's Business Daily
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
September 20, 2024
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
Via
The Motley Fool
US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices
September 20, 2024
FTC files a complaint against CVS, Cigna, and UnitedHealth's PBMs, accusing them of inflating insulin prices through a rebate-driven system. The case aims to address unfair practices and improve access...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players
September 20, 2024
Novo Nordisk announced positive Phase 2a trial results for monlunabant, showing significant weight loss with a 10 mg dose. However, investors reacted to limited gains at higher doses. Corbus...
Via
Benzinga
Corbus Pharma (CRBP) Stock Drops 60% After Novo Nordisk's Cannabinoid-Based Weight Loss Drug Trial Disappoints
September 20, 2024
Corbus Pharmaceuticals and Novo Nordisk stocks plunge following cannabinoid receptor drug trials, raising concerns over weight loss results.
Via
Benzinga
Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity
September 19, 2024
Via
Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $5,700 Today
September 11, 2024
Via
Benzinga
Novo Nordisk Stock Declines After Headline Results From Mid-Stage Study Of Monlunabant In Obese Patients
September 20, 2024
Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 mg daily dose compared to placebo.
Via
Benzinga
Novo Dives — And Corbus Crashes — After New Weight-Loss Drug Causes Neuropsychiatric Effects
September 20, 2024
Shares of Corbus, which is working on a similar drug, also crashed on Novo Nordisk's news.
Via
Investor's Business Daily
European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
September 20, 2024
Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart failure symptoms, physical limitations, and exercise function in patients with...
Via
Benzinga
Hims & Hers To Offer Access To Compounded Diabetes And Weight Loss Drugs For Just $99/Month To Certain Professional Personnel
September 19, 2024
Hims & Hers Health will offer compounded GLP-1 weight-loss medications for as low as $99 per month to eligible U.S. military personnel, veterans, teachers, nurses, and first responders. The telehealth...
Via
Benzinga
Viking Therapeutics Is Having a Year to Remember: Time to Buy?
September 19, 2024
Viking Therapeutics Inc. (NASDAQ: VKTX) has surged 238% year-to-date and 326% over the past year, far outpacing its sector and market.
Via
MarketBeat
Evaluating Novo Nordisk: Insights From 8 Financial Analysts
September 09, 2024
Via
Benzinga
What the Options Market Tells Us About Novo Nordisk
September 06, 2024
Via
Benzinga
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks
September 19, 2024
This strategic play will take time to pay off, but it could keep growth going.
Via
The Motley Fool
Novo Nordisk Inks $600M Genetic Medicines Pact With Canadian Firm To Target Cardiometabolic Indications
September 18, 2024
Wednesday, Canada-based NanoVation Therapeutics announced a multi-year partnership with Novo Nordisk A/S (NYSE:NVO) to advance the ...
Via
Benzinga
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
September 17, 2024
Telemedicine once seemed like it was going to revolutionize healthcare.
Via
The Motley Fool
2 Unstoppable Healthcare Stocks to Buy Right Now for Less Than $200
September 14, 2024
No need to break the bank to get in on these excellent companies.
Via
The Motley Fool
Time To Invest And Or Trade In Bio-Tech Stocks?
September 13, 2024
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help...
Via
Talk Markets
Topics
ETFs
Stock Market Rally Revives; Apple iPhone 16, Nvidia, Oracle, Adobe In Focus: Weekly Review
September 13, 2024
The major indexes reclaimed key levels and many leaders flashed buy signals.
Via
Investor's Business Daily
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
September 12, 2024
An investment in these players today could score a big win down the road.
Via
The Motley Fool
Why Roche Holdings Stock Withered on Wednesday
September 11, 2024
The company had a dispiriting update to offer about an investigational drug.
Via
The Motley Fool
Why Viking Therapeutics Stock Rocked the Market Today
September 11, 2024
The biotech continued to get attention from both pundits and investors, thanks largely to its investigational obesity drug.
Via
The Motley Fool
Novo Nordisk Jumps After New Weight-Loss Pill Tops Wegovy; Eli Lilly, Viking Shares Rise
September 11, 2024
The company is working on a drug that targets GLP-1 and amylin to improve weight loss.
Via
Investor's Business Daily
Ozempic Maker Novo Nordisk Touts Encouraging Data From New Obesity Pill Showing Double Weight Loss Compared To Wegovy
September 11, 2024
Novo Nordisk presented data on its next-generation weight-loss candidate, amycretin, which showed a significant 13% weight loss in three months with adult participants.
Via
Benzinga
Is Hims & Hers Health the Next Teladoc?
September 11, 2024
Telemedicine was one of the most in-demand services during the height of the COVID-19 pandemic.
Via
The Motley Fool
Exposures
COVID-19
Novo Nordisk Reports Positive Results Of Weight-Loss Drug Liraglutide For Children As Young As 6, Eyes FDA And EMA Approval
September 11, 2024
Novo Nordisk has announced that its weight-loss drug liraglutide is safe and effective for children as young as six. The company-funded study revealed a 7.4% reduction in body-mass index for children...
Via
Benzinga
Exposures
Product Safety
Is Merck Stock Undervalued After Its Colossal Earnings Growth?
September 07, 2024
Merck has seen its earnings invert over the past 12 months, driving earnings grow in its sector. What's going on with this pharma giant?
Via
MarketBeat
Billionaires Are Buying Viking Therapeutics Stock Left and Right. Should You Follow Their Lead?
September 07, 2024
The huge demand for effective new weight management drugs has billionaire investors feeling bullish about this stock.
Via
The Motley Fool
Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts
September 05, 2024
Goldman Sachs downgrades Novartis to Neutral, citing a lack of immediate innovative catalysts and limited stock growth potential.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
60
61
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.